| Mr Charles D Varela, MD | |
|
2110 East Main, Mountain View, AR 72560 | |
| (870) 269-8300 | |
| (870) 269-5630 |
| Full Name | Mr Charles D Varela |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 39 Years |
| Location | 2110 East Main, Mountain View, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518071638 | NPI | - | NPPES |
| 128893001 | Medicaid | AR | |
| 200030482 | Other | AR | MEDICARE RAILROAD |
| 18528000000 | Other | AR | QUAL CHOICE PROVIDER # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | E-0781 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stone County Medical Center | Mountain view, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| White River Health System Inc | 0143134270 | 150 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
In the past three decades, in vitro fertilization has gone from an experimental procedure to being more common. Pregnancies enabled by IVF frequently have more difficulties, with children born earlier and smaller even among singleton births.
Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.
› Verified 9 days ago
| Entity Name | Mercy Health Northwest Arkansas Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265490916 PECOS PAC ID: 0648177873 Enrollment ID: O20031216000788 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
In the past three decades, in vitro fertilization has gone from an experimental procedure to being more common. Pregnancies enabled by IVF frequently have more difficulties, with children born earlier and smaller even among singleton births.
Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.
› Verified 9 days ago
| Entity Name | Ozark Orthopaedic And Hand Surgery Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629156252 PECOS PAC ID: 3870633068 Enrollment ID: O20091219000043 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
In the past three decades, in vitro fertilization has gone from an experimental procedure to being more common. Pregnancies enabled by IVF frequently have more difficulties, with children born earlier and smaller even among singleton births.
Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.
› Verified 9 days ago
| Entity Name | Mercy Health Northwest Arkansas Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538460662 PECOS PAC ID: 0648177873 Enrollment ID: O20110406000912 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
In the past three decades, in vitro fertilization has gone from an experimental procedure to being more common. Pregnancies enabled by IVF frequently have more difficulties, with children born earlier and smaller even among singleton births.
Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.
› Verified 9 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922387505 PECOS PAC ID: 0143134270 Enrollment ID: O20110908001933 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
In the past three decades, in vitro fertilization has gone from an experimental procedure to being more common. Pregnancies enabled by IVF frequently have more difficulties, with children born earlier and smaller even among singleton births.
Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Charles D Varela, MD Po Box 1580, Mountain View, AR 72560-1580 Ph: (870) 269-8300 | Mr Charles D Varela, MD 2110 East Main, Mountain View, AR 72560 Ph: (870) 269-8300 |
News Archive
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
In the past three decades, in vitro fertilization has gone from an experimental procedure to being more common. Pregnancies enabled by IVF frequently have more difficulties, with children born earlier and smaller even among singleton births.
Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.
› Verified 9 days ago